Biosynex (ALBIO) - Total Liabilities

Latest as of June 2025: €105.13 Million EUR ≈ $122.91 Million USD

Based on the latest financial reports, Biosynex (ALBIO) has total liabilities worth €105.13 Million EUR (≈ $122.91 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Biosynex (ALBIO) cash conversion ratio to assess how effectively this company generates cash.

Biosynex - Total Liabilities Trend (2006–2024)

This chart illustrates how Biosynex's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Biosynex's assets to evaluate the company's liquid asset resilience ratio.

Biosynex Competitors by Total Liabilities

The table below lists competitors of Biosynex ranked by their total liabilities.

Company	Country	Total Liabilities
Hanchang KO:005110	Korea	₩85.91 Billion
Laser Photonics Corporation Common Stock NASDAQ:LASE	USA	$13.36 Million
Hank Payments Corp V:HANK	Canada	CA$12.55 Million
Kingsmen C.M.T.I. Public Company Limited BK:K	Thailand	฿367.99 Million
Currys PLC LSE:CURY	UK	GBX3.65 Billion
Clean Seas Seafood Limited F:C7S	Germany	€25.00 Million
Ovanti Ltd AU:OVT	Australia	AU$3.96 Million
NexturnBioscience Co. Ltd KQ:089140	Korea	₩128.65 Billion

Liability Composition Analysis (2006–2024)

This chart breaks down Biosynex's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biosynex (ALBIO) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.37	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.70	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Biosynex's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Biosynex (2006–2024)

The table below shows the annual total liabilities of Biosynex from 2006 to 2024.

Year	Total Liabilities	Change
2024-12-31	€114.19 Million ≈ $133.50 Million	-2.74%
2023-12-31	€117.41 Million ≈ $137.27 Million	+25.96%
2022-12-31	€93.21 Million ≈ $108.98 Million	-7.84%
2021-12-31	€101.14 Million ≈ $118.24 Million	+69.17%
2020-12-31	€59.78 Million ≈ $69.89 Million	+252.37%
2019-12-31	€16.97 Million ≈ $19.84 Million	+66.35%
2018-12-31	€10.20 Million ≈ $11.92 Million	-12.10%
2017-12-31	€11.60 Million ≈ $13.57 Million	-23.39%
2016-12-31	€15.15 Million ≈ $17.71 Million	+122.01%
2015-12-31	€6.82 Million ≈ $7.98 Million	+103.94%
2014-12-31	€3.35 Million ≈ $3.91 Million	-0.24%
2013-12-31	€3.35 Million ≈ $3.92 Million	-8.63%
2012-12-31	€3.67 Million ≈ $4.29 Million	+297.02%
2011-12-31	€924.34K ≈ $1.08 Million	-1.96%
2010-12-31	€942.86K ≈ $1.10 Million	-2.39%
2009-12-31	€965.95K ≈ $1.13 Million	+32.14%
2008-12-31	€731.01K ≈ $854.63K	+47.38%
2007-12-31	€496.00K ≈ $579.88K	+16.98%
2006-12-31	€424.00K ≈ $495.70K	--

About Biosynex

PA:ALBIO France Medical Devices

Market Cap

$16.81 Million

€14.38 Million EUR

Market Cap Rank

#25694 Global

#426 in France

Share Price

€0.78

Change (1 day)

-2.50%

52-Week Range

€0.48 - €1.51

All Time High

€25.28